36 Breast Cancer Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Breast Cancer Studies in San Francisco

NCT02620852Recruiting

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended t...

San Francisco, CANA100,000 participantsUniversity of California, San Francisco

View Study Details

NCT03053193Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing ...

San Francisco, CA30,000 participantsAgendia

View Study Details

NCT01042379Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learn...

San Francisco, CAPHASE25,000 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT07391774Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast...

San Francisco, CAPHASE31,978 participantsNational Cancer Institute (NCI)

View Study Details

NCT06393374Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...

San Francisco, CAPHASE31,530 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06445738Recruiting

Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the ca...

San Francisco, CANA1,400 participantsBreast Cancer Trials, Australia and New Zealand

View Study Details

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

San Francisco, CAPHASE31,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07085767Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for...

San Francisco, CAPHASE31,000 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT04862663Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact...

San Francisco, CAPHASE3895 participantsAstraZeneca

View Study Details

NCT05232916Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk f...

San Francisco, CAPHASE3750 participantsGreenwich LifeSciences, Inc.

View Study Details

NCT06435429Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the...

San Francisco, CAPHASE3550 participantsJazz Pharmaceuticals

View Study Details

NCT06982521Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER...

San Francisco, CAPHASE3540 participantsRelay Therapeutics, Inc.

View Study Details

NCT04893109Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as ...

San Francisco, CAPHASE2500 participantsDana-Farber Cancer Institute

View Study Details

NCT06075953Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effe...

San Francisco, CAPHASE2400 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT05377996Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors...

San Francisco, CAPHASE1360 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06533826Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan fol...

San Francisco, CAPHASE2357 participantsAna C Garrido-Castro, MD

View Study Details

NCT04606446Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a sin...

San Francisco, CAPHASE2320 participantsPfizer

View Study Details

NCT04802759Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments be...

San Francisco, CAPHASE1316 participantsHoffmann-La Roche

View Study Details

NCT07100106Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participa...

San Francisco, CAPHASE1285 participantsGenentech, Inc.

View Study Details

NCT06648278Recruiting

Patient Care Outreach, Navigation, Technology and Support 2.0

This is a feasibility study employing virtual patient navigation for underserved individuals who speak English, Chinese or Spanish and were diagnosed with breast cancer or cardiovascular disease to de...

San Francisco, CANA260 participantsUniversity of California, San Francisco

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

San Francisco, CAPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

NCT06993844Recruiting

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors...

San Francisco, CAPHASE1233 participantsEnsem Therapeutics

View Study Details

NCT06099769Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor...

San Francisco, CAPHASE2201 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05020574Recruiting

Microbiome and Association With Implant Infections

The most common tissue expander-related infections are from Staphylococcus and Pseudomonas species. In addition, from breast tissue microbiome studies, Staphylococcus and Pseudomonas show variable abu...

San Francisco, CAPHASE2200 participantsUniversity of California, San Francisco

View Study Details

NCT06551116Recruiting

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are...

San Francisco, CA200 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT05508906Recruiting

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis ...

San Francisco, CAPHASE1190 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06369285Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-n...

San Francisco, CAPHASE2150 participantsPuma Biotechnology, Inc.

View Study Details

NCT06774027Recruiting

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple n...

San Francisco, CA100 participantsUniversity of California, San Francisco

View Study Details

NCT05366699Recruiting

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpos...

San Francisco, CANA80 participantsStanford University

View Study Details

NCT07546331Recruiting

Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

This study compares measurements of body composition to outcomes of breast reconstruction....

San Francisco, CA40 participantsUniversity of California, San Francisco

View Study Details

NCT04434040Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

San Francisco, CAPHASE240 participantsDana-Farber Cancer Institute

View Study Details

NCT06224673Recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that...

San Francisco, CAPHASE236 participantsLaura Huppert, MD, BA

View Study Details

NCT03990896Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation....

San Francisco, CAPHASE230 participantsMassachusetts General Hospital

View Study Details

NCT06518057Recruiting

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients wit...

San Francisco, CAPHASE222 participantsUniversity of Washington

View Study Details

NCT05902507Recruiting

Magnetic Resonance Imaging in Radiotherapy for Breast Cancer

This is a single-center, prospective pilot study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatment (RT) for brea...

San Francisco, CA20 participantsUniversity of California, San Francisco

View Study Details

NCT05964504Recruiting

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an IL...

San Francisco, CA12 participantsUniversity of California, San Francisco

View Study Details

About Breast Cancer Clinical Trials in San Francisco

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 36 breast cancer clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 149,235 participants. Research is being sponsored by University of California, San Francisco, Agendia, QuantumLeap Healthcare Collaborative and 23 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in San Francisco — FAQ

Are there breast cancer clinical trials in San Francisco?

Yes, there are 36 breast cancer clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 36 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 17, 2026 from ClinicalTrials.gov